MY152178A - Substituted 8-[6-amino-3-pyridyl]xanthines - Google Patents

Substituted 8-[6-amino-3-pyridyl]xanthines

Info

Publication number
MY152178A
MY152178A MYPI20084937A MY152178A MY 152178 A MY152178 A MY 152178A MY PI20084937 A MYPI20084937 A MY PI20084937A MY 152178 A MY152178 A MY 152178A
Authority
MY
Malaysia
Prior art keywords
xanthines
pyridyl
amino
substituted
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Wang Guoquan
Robert D Thompson
Jayson M Rieger
Original Assignee
Dogwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dogwood Pharmaceuticals Inc filed Critical Dogwood Pharmaceuticals Inc
Publication of MY152178A publication Critical patent/MY152178A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20084937 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines MY152178A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US80556406P 2006-06-22 2006-06-22
US11/811,823 US7884100B2 (en) 2006-06-16 2007-06-12 Substituted 8-[6-amino-3-pyridyl]xanthines

Publications (1)

Publication Number Publication Date
MY152178A true MY152178A (en) 2014-08-15

Family

ID=56290980

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20084937 MY152178A (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Country Status (18)

Country Link
US (2) US7884100B2 (enExample)
EP (1) EP2029143B1 (enExample)
JP (1) JP5417558B2 (enExample)
KR (1) KR101413404B1 (enExample)
CN (1) CN103145712A (enExample)
AU (1) AU2007261568B2 (enExample)
BR (1) BRPI0712001B8 (enExample)
CA (1) CA2655598C (enExample)
DK (1) DK2029143T3 (enExample)
EA (1) EA016791B1 (enExample)
ES (1) ES2548437T3 (enExample)
HU (1) HUE026457T2 (enExample)
IL (1) IL195916A (enExample)
MX (1) MX2008015954A (enExample)
MY (1) MY152178A (enExample)
NZ (1) NZ597222A (enExample)
PL (1) PL2029143T3 (enExample)
PT (1) PT2029143E (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
NZ545715A (en) * 2003-08-25 2009-02-28 Adenosine Therapeutics Llc Substituted 8-heteroaryl xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
WO2006091936A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CN117337263A (zh) 2021-05-18 2024-01-02 阿多维特有限责任公司 作为a2b拮抗剂的含环酰胺的吡啶基黄嘌呤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
BR0108454A (pt) * 2000-02-17 2003-04-01 Cv Therapeutics Inc Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
KR100937620B1 (ko) 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2443023A1 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
NZ545715A (en) * 2003-08-25 2009-02-28 Adenosine Therapeutics Llc Substituted 8-heteroaryl xanthines
SI1789053T1 (sl) 2004-09-01 2012-09-28 Gilead Sciences Inc Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev
WO2006028840A2 (en) 2004-09-03 2006-03-16 United States Postal Service Methods and systems for providing an enterprise supply management portal
AU2005295654B2 (en) 2004-10-15 2011-04-14 Gilead Sciences, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
CN101198608B (zh) 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
RU2457842C2 (ru) * 2006-03-17 2012-08-10 Гайлид Пало Альто, Инк. Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
AU2006344750A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist

Also Published As

Publication number Publication date
CA2655598A1 (en) 2007-12-27
EA200900010A1 (ru) 2009-10-30
BRPI0712001B1 (pt) 2020-04-07
MX2008015954A (es) 2009-03-06
KR101413404B1 (ko) 2014-06-27
JP2010500284A (ja) 2010-01-07
US8258142B2 (en) 2012-09-04
US20080004292A1 (en) 2008-01-03
ES2548437T3 (es) 2015-10-16
IL195916A0 (en) 2009-09-01
EP2029143B1 (en) 2015-07-08
NZ597222A (en) 2013-06-28
JP5417558B2 (ja) 2014-02-19
KR20090029268A (ko) 2009-03-20
US20110082139A1 (en) 2011-04-07
AU2007261568A1 (en) 2007-12-27
EP2029143A2 (en) 2009-03-04
EP2029143A4 (en) 2009-07-15
CA2655598C (en) 2014-10-28
AU2007261568B2 (en) 2013-05-16
PL2029143T3 (pl) 2015-12-31
BRPI0712001B8 (pt) 2021-05-25
DK2029143T3 (en) 2015-09-21
EA016791B1 (ru) 2012-07-30
BRPI0712001A2 (pt) 2012-01-10
US7884100B2 (en) 2011-02-08
PT2029143E (pt) 2015-10-20
CN103145712A (zh) 2013-06-12
HUE026457T2 (en) 2016-05-30
IL195916A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
IL195006A0 (en) Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
IL190336A0 (en) Imidazopyridine derivatives as a2b adenosine receptor antagonists
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
EA200900010A1 (ru) Замещенные 8-[6-амино-3-пиридил]ксантины
WO2006091898A3 (en) Pyrazolyl substituted xanthines
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
HU0400405D0 (en) Novel compounds
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
WO2009043320A3 (en) Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives
WO2008020405A3 (en) Azetidine compounds as orexin receptor antagonists
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
IL178365A (en) Selective antagonists of a2a adenosine receptors
BRPI0708965B8 (pt) composição farmacêutica de metilnaltrexona
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors
MY145633A (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TN2009000040A1 (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists
UA105164C2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
WO2005040155A8 (en) Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists
WO2008027585A3 (en) Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors